Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.
about
eIF5A isoforms and cancer: two brothers for two functions?Trespassing cancer cells: 'fingerprinting' invasive protrusions reveals metastatic culpritsA novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformationPrognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patientsExpression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapiesCisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancerPrognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer.ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinomaOverexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancerA Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors.Biological Relevance and Therapeutic Potential of the Hypusine Modification System.Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinomaThe translation factor eIF5A and human cancer.Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.Translational control in cancer etiology.Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samplesEIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo.MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2.Roles of eukaryotic initiation factor 5A2 in human cancer.GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cellsExpression of eukaryotic translation initiation factor 5A-2 (eIF5A-2) associated with poor survival in gastric cancer.Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer.EIF5A2 is a novel chemoresistance gene in breast cancer.Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.Down-regulation of eIF5A-2 prevents epithelial-mesenchymal transition in non-small-cell lung cancer cells.Eukaryotic translation initiation factors and cancer.Protein-protein-interaction network organization of the hypusine modification system.N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma.Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma.Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells.MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2
P2860
Q26830163-A1D14024-33DB-4F57-A2F5-8B59E66090D6Q26997307-24B50280-869C-49E8-8FCD-46A4EF14FED7Q28510855-741E7725-A581-46F4-9F94-67F79BD077A5Q33944623-8100D9CD-1956-4301-85AE-8757E891ECE7Q34395707-6640D4AC-71E2-4860-9E86-D0E187D35713Q34515582-FEF7B565-127B-4614-90A0-CA49713B6B1FQ34518559-49C7B138-274C-4597-B7E1-7132D9908ECAQ34575589-1A7BBE32-4D47-49B3-82A0-39AB6DA7E5DAQ35051418-AA4F74FA-D23C-4491-B84F-B8D5B8144A50Q35202594-F90428E7-BB0F-417F-92FB-854BC20DBC0FQ35716316-7D1792C2-586C-49F8-9F08-D2BC4059DC04Q35883784-ECADAECE-B0DC-4B03-8F9B-C5763A970924Q36109579-22400858-F4E6-43E4-B9DB-D5CB27EA8DABQ36413366-AD268E98-AE1D-4561-A5CE-F4FE59405573Q36519353-FDEE9097-FD32-48A8-A74F-9252E0B800E6Q36544520-2CFFDA1F-E729-40DC-B484-448BB27849B5Q36555212-EBA4A6BC-B243-422E-90F0-507F6E20338FQ37520334-0B96BD11-E1BE-41D2-A24B-357B094C70F8Q37681730-1C2E9CB8-0320-41D6-AD71-2018D5536472Q37685242-A8D05693-6F30-4A84-98B7-03866F5006D1Q38163977-39D1E7DB-134A-4A5B-A6ED-96CC6C0056A7Q38701796-057DBCAE-8D47-4166-B711-1218C01475CAQ38843125-8DEC9C39-B658-4189-A405-663FBACC497DQ38881007-BF472AF6-08AB-43BC-9FF3-4072D9220EC3Q39014521-D589F64E-F84E-4C68-AF55-43AB6E4BD0EFQ39068047-7496D268-36A3-4D3F-960E-3532B8286DF8Q39144255-BE90C67A-D585-4EE7-BDEE-B6AEAFA7188CQ39400409-643D8096-F4D7-48D9-BD9B-B919D4FBDBBDQ41295369-18B15F6C-034B-4DC8-B707-DFD90C916BE7Q41672712-AF5E4863-481A-4AD4-96E6-3D69E59A204BQ42031208-CE948E64-C5B4-475F-BC13-4CECDB69EC36Q42639936-A3723DAE-6A0B-40E1-B755-1BF1748F6553Q47422423-6EEE3B5A-EB7B-4359-9A32-62DE6259BB52Q48879179-2B4B4B99-2386-43FE-AE9E-8004B1B3027BQ49335206-54EAC78A-B28D-494D-8C80-80320B11E506Q51049728-F0A7B7F1-A4EF-4DC0-A38E-73B90F2D4E07Q52655137-81B5DA8B-61ED-4F6D-8A5A-7C59CD1086DBQ58800121-95A1BE07-C882-4941-BA69-FB60A40A60B2
P2860
Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@ast
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@en
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@nl
type
label
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@ast
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@en
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@nl
prefLabel
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@ast
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@en
Overexpression of eIF5A-2 is a ...... all cell lung cancer patients.
@nl
P2093
P2860
P356
P1476
Overexpression of eIF5A-2 is a ...... mall cell lung cancer patients
@en
P2093
Bin-Kui Li
Hong-Yun Zhao
Meng-Zhong Liu
Xiu-Wu Bian
Yan-Hui Liu
Yi-Xin Zeng
P2860
P304
P356
10.1002/IJC.25669
P577
2011-07-01T00:00:00Z